SGLT-2 inhibitors may positively affect NAFLD and its progression to liver fibrosis and cirrhosis by improving insulin resistance and reducing hepatic fat deposition (161). This evidence concerns the gene SLC5A2 and metabolic dysfunction-associated steatotic liver disease.